Instil Bio Inc (TIL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.58-1.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TIL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TIL — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Why it matters: An improvement in sector growth could benefit Instil Bio and its peers in the healthcare space.
Supportive ifHealthcare sector revenue growth speeds up to over 10% compared to last year.
Worry ifHealthcare sector revenue growth slows down to under 5% compared to last year.
Why it matters: Better net loss per share shows improved cost control and efficiency.
Supportive ifNet loss per share reported below $0.60 in the next quarterly update.
Worry ifNet loss per share remains above $0.60 in the next quarterly update.
Why it matters: A high net loss per share could signal ongoing financial struggles. Investors will want to see if this trend changes.
Worry ifNet loss per share remains at or above $10.70 for fiscal year 2025.
Less concerning ifNet loss per share decreases below $10.70 for fiscal year 2025.
Why it matters: Improvement in net loss per share signals better financial health and cost control.
Supportive ifNet loss per share for Q2 is reported below $0.62.
Worry ifNet loss per share remains at or above $0.62 in Q2.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$74 on $10,000 · ±0.7% | How much price usually moves either way. |
| Bad day | $716 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,886 loss on $10,000 · 78.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: High operating costs may show problems and affect cash flow.
Worry ifOperating costs are over $6 million in the next update.
Less concerning ifOperating costs stay under $6 million in the next update.
Why it matters: The company is using cash quickly. This could hurt its ability to keep running. Investors want to see better cash management.
Worry ifCash from operations remains negative, worse than -$1.3M in 2026-Q1.
Less concerning ifCash from operations is now positive or has improved a lot.
Why it matters: Progress on acquisitions could signal growth and strengthen the pipeline.
Supportive ifLook for news about a specific acquisition or licensing deal.
Worry ifNo news or failed talks on acquisitions in the next quarter.
Why it matters: A strong earnings report could signal ongoing momentum after the recent earnings beat.
Supportive ifQ2 earnings results are more than 5% better than what analysts expected.
Worry ifQ2 earnings results fall short of analyst expectations by more than 5%.
Why it matters: A drop below this level could signal cash management issues. Instil needs to fund its operations beyond 2027.
Worry ifCash position is below $69 million in the next quarterly update.
Less concerning ifCash position remains above $69 million in the next quarterly update.
Why it matters: Purchases or licensing deals could improve Instil's pipeline and help it grow.
Supportive ifA press release will share details about a specific purchase or licensing deal.
Worry ifNo news on acquisition efforts in the next quarter.
Why it matters: Smaller operating losses show that costs are being managed well.
Supportive ifOperating losses were below $7.0 million in Q2.
Worry ifOperating losses were at or above $7.0 million in Q2.
Why it matters: Updates on cash will show if Instil can fund operations past 2026.
Worry ifCash position reported above $74.7 million in Q2 earnings.
Less concerning ifCash position reported below $74.7 million in Q2 earnings.